Table of Contents
<< Previous Issue | Feb 2021 (Vol: 2021, Issue: 2) | Next Issue >> |
- Section: Mergers & Acquisitions
-
Horizon Continues to Build Rare Disease Pipeline with US$3.05 B Viela Buy
-
Boehringer Ingelheim Buys ADC Specialist NBE-Therapeutics for US$1.43 B
- Section: Research & Development
-
Bayer Partners with Atara Therapeutics for Mesothelin-directed CAR-T Therapies
-
Novartis Licenses Anti-PD1 Antibody Tislelizumab from BeiGene in US$2.2 B Deal
-
Coherus Catapults into Immuno-oncology Field with US$1.8 B Junshi Alliance
-
Merck Ventures Further into Natural Killer Therapies with US$1.9 B Artiva Alliance